Announcement
IMPORTANT NOTIFICATION: Zantac (Ranitidine) Recall
Dear Doctor, Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules. The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall. We are informing you as the potentially…
Read MoreANNOUNCEMENT – Aspen Pharma – QUARANTINE STATUS LIFTED and URGENT PRODUCT DEFECT CORRECTION – ENDONE oxycodone hydrochloride 5mg tablet pack
Aspen Pharma is lifting the current retail level quarantine and undertaking a product defect correction for one batch Endone tablets -Batch CW612. We are contacting you as our records indicate that units from this particular batch may have been supplied to your organisation. Download Letter Download Letter – TGA
Read MoreANNOUNCEMENT – Aspen Pharmacare – URGENT MEDICINE RECALL FOR PRODUCT CORRECTION of SPAN K (potassium chloride) 600mg Tablets TGA reference: RC-2017-RN-00300-1
The bottle cap on Span K (potassium chloride) 600mg tablets is not child resistant. Apsen Pharmacare is conducting a recall for product correction to replace the current plain white cap with an enclosed child resistant cap. Future stock will include a child resistant cap.
Read MoreANNOUNCEMENT – Aspen AstraZeneca Anaesthetics Portfolio Agreement
Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”).
Read MoreFerinject® (ferric carboxymaltose) 10ml (500mg) available on the Pharmaceutical Benefits Scheme (PBS) from the 1st June, 2014
Aspen Australia is pleased to advise that from the 1st June, 2014 Ferinject® (ferric carboxymaltose) 10ml (500mg) is available on the Pharmaceutical Benefits Scheme (PBS) as a drug for iron deficiency anaemia.# Ferinject® (ferric carboxymaltose) is available in Australia for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.
Read MoreAspen Pharmacare Australia announces a new partnership with Eli Lilly Australia for Zyprexa®
Aspen Pharmacare Australia Pty Ltd (Aspen) is pleased to announce a new partnership with Eli Lilly Australia (Lilly) for Zyprexa® (olanzapine), a market leading medication for schizophrenia and bipolar disorder
Read MoreFormal Agreement Reached for $900 Million Sale of Pharmaceuticals Division to Aspen Pharmacare
On 16 August 2010, Sigma announced that it had agreed in principle to sell its Pharmaceuticals Division to the Aspen Pharmacare Holdings Limited group of companies for A$900 million.
Read MoreAspen to distribute Merck products
Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
Read MoreStephen Saad, CEO of Aspen Holdings, comments on Sigma purchase
An interview of Stephen Saad, CEO of Aspen Holdings.
Read MoreAspen Announcement to JSE
Announcement regarding the acquisition of the pharmaceutical business of Sigma Pharmaceuticals Limited by Aspen.
Read More